GNBT Generex Biotechnology Corp. featured news, full reports, and detailed charts
Generex Biotechnology Corp. (GNBT) Wrap Up:
Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company’s products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Ener...www.generex.com
43 Employees
Founded in 1983
Generex Biotechnology Corp. (GNBT*(D):NASDAQ)
LAST $0.50 USD
CHANGE TODAY -0.01 -1.96%
VOLUME 2.1M
*(D) = Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Generex Biotechnology Corp. (GNBT)
|
OPEN
$0.51
|
PREVIOUS CLOSE
$0.51
|
|
|
DAY HIGH
$0.51
|
DAY LOW
$0.46
|
|
|
52 WEEK HIGH
06/5/09 - $1.14
|
52 WEEK LOW
03/9/09 - $0.08
|
|
|
MARKET CAP
123.5M
|
AVERAGE VOLUME 3 mo
1.4M
|
|
|
DILUTED EPS TTM
$-0.33
|
SHARES OUTSTANDING
246.9M
|
|
|
GNBT Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
GNBT Top Compensated Officers
Ms. Anna E. Gluskin
Chairperson, Chief Executive Officer and Pres...
Age: 58
Total Annual Compensation: $525.0K
Ms. Rose C. Perri
Chief Financial & Operating Officer, Principa...
Age: 42
Total Annual Compensation: $420.0K
Mr. Mark A. Fletcher Esq.
Executive Vice President and General Counsel
Age: 43
Total Annual Compensation: $315.0K
Dr. Gerald Bernstein M.D.
Vice President of Medical Affairs
Age: 76
Total Annual Compensation: $200.0K
Executives, Board Directors
Compensation as of Fiscal Year 2009.
Key developments for Generex Biotechnology Corp. (GNBT)
Generex Biotechnology Corp. Receives Purchase Order for Generex Oral-lyn(TM) for Algerian Market
10/21/2009
Generex Biotechnology Corp. has received its first purchase order for Generex Oral-lyn(TM) from Continental Pharm Laboratories, a pharmaceutical products distributor in Algeria. The order consists of 10,000 canisters of Generex Oral-lyn(TM) which will be filled by the Company's Middle Eastern branch office, Generex MENA (Middle East and Northern Africa), located in Dubai Healthcare City.
Generex Launches Generex Oral-lyn(TM) in Algeria
10/16/2009
Generex Biotechnology Corp. announced that, at a conference earlier this week in Oran, Algeria, Generex, together with Continental Pharma Laboratories, the Company's importation, marketing, distribution, and sales agent in Algeria, announced the launch of commercial sales of Generex Oral-lyn(TM) in Algeria. The product has been approved for importation and commercial marketing and sale in Algeria, and will be marketed and sold for the treatment of patients with Type-1 or Type-2 diabetes. The size of the diabetes population in the Eastern Mediterranean and Middle East region is approximately 24,500,000. The launch of Generex Oral-lyn(TM) took place at Royal Hotel, Oran.
Generex Biotechnology Corp. - Special/M&A Call
10/14/2009
To update the investment community on the company's flagship product, Generex Oral-lyn(TM) and other corporate activities
GNBT Competitors
| Company | Last | Change |
| Apollo Consolidated Limited | A$0.01 AUD | -0.002 |
| Aradigm Corp | $0.16 USD | +0.005 |
| CEL-SCI Corp | $1.30 USD | +0.01 |
| Emisphere Technologies | $0.67 USD | 0.00 |
| MDRNA Inc | $0.82 USD | -0.0299 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | GNBT | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 87.4x |
|
| Price/Book | 7.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 97.3x |
|
|
GNBT |
||
|
GNBT transactions
| Type Date |
Target |
|
Private Placement
September 11, 2009 |
-- |
|
Private Placement
August 6, 2009 |
-- |
|
Private Placement
June 15, 2009 |
-- |
More Recent News About Generex Biotechnology Corp.
More news for GNBT
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Show all filings for GENEREX BIOTECHNOLOGY CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for GENEREX BIOTECHNOLOGY CORP 20-Oct-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for...Click here to read the whole Article (external link)
Generex: Going Concern Qualification
WORCESTER, Mass., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Pursuant to Nasdaq Marketplace Rule 5250(b)(2), Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com) today announced that its consolidated financial statements for the fiscal year ended July 31, 2009 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on October 14, 2009 contained a going concern qualification from its independent registered public accounting firm. Nasdaq Marketplace Rule 5250(b)(2) requires separate public disclosure of a previously issued audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company's financial statements for the fiscal year ended July 31, 2009 or to its Annual Report on Form 10-K. About Generex Biotechnology Corporation Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administere...Click here to read the whole Article (external link)
Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
DALLAS, Oct. 27, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Generex Biotechnologies Corp. (Nasdaq:GNBT - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. The investment report on Generex Biotechnologies Corp. (Nasdaq:GNBT - News) should be of particular interest to other biotechnology companies: CPEX Pharmaceuticals Inc. (Nasdaq:CPEX - News), MannKind Corp. (Nasdaq:MNKD - News), Novo Nordisk (NYSE:...Click here to read the whole Article (external link)
Generex Biotechnology Receives Purchase Order for Generex Oral-lyn(TM) for Algerian Market
WORCESTER, Mass., Oct. 21, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced it has received its first purchase order for Generex Oral-lyn(TM) from Continental Pharm Laboratories, a pharmaceutical products distributor in Algeria. The order consists of 10,000 canisters of Generex Oral-lyn(TM) which will be filled by the Company's Middle Eastern branch office, Generex MENA (Middle East and Northern Africa), located in Dubai Healthcare City. "We are pleased that the first order for Generex Oral-lyn(TM) has come so quickly on the heels of the launch in Algeria last week," said Bill Abajian, Sr. Executive Advisor, Global Business Development and Licensing for the Company. "It is a testament to the enthusiasm demonstrated by the endocrinologists to introduce Generex Oral-lyn(TM) to their patients' treatment paradigm and to the education and training strategy tailored to the region and implemented by the Generex MENA office." Generex MENA is responsible for over 20 countries and has relationships with over 31 distributors for each of the various p...Click here to read the whole Article (external link)
Generex Announces That It Will Not Exercise Its Rights to Issue and Sell Stock Under Its At Market Issuance Sales Agreement With WM Smith Until Further Notice
WORCESTER, Mass., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that, in light of general market conditions, Generex will not exercise its right to issue and sell shares of its common stock under the At Market Issuance Sales Agreement that it entered into with Wm Smith & Co. on October 14, 2009 until further notice. About Generex Biotechnology Corporation Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, ...Click here to read the whole Article (external link)
Generex Receives Confirmation of Extension of Compliance Period From NASDAQ
WORCESTER, Mass., Nov. 10, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has received confirmation from The NASDAQ Stock Market that the Company will be provided with an additional 180 calendar day period to regain compliance with the Capital Market's listing maintenance requirements. Subject to the exercise of Staff discretion, the Company will regain compliance if the bid price of the Company's common stock on the Capital Market closes at $1.00 per share or more for a minimum of 10 consecutive business days before May 5, 2010. About Generex Biotechnology Corporation Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(...Click here to read the whole Article (external link)
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Show all filings for GENEREX BIOTECHNOLOGY CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for GENEREX BIOTECHNOLOGY CORP 30-Oct-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for...Click here to read the whole Article (external link)
Generex has 180 days to regain listing compliance
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Show all filings for GENEREX BIOTECHNOLOGY CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for GENEREX BIOTECHNOLOGY CORP 10-Nov-2009Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informatio...Click here to read the whole Article (external link)
Would you like to leave a comment about Generex Biotechnology Corp. GNBT
Find out what social network information about Generex Biotechnology Corp. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Generex Biotechnology Corp. there is more great information available at Realpennies.com